News und Analysen
THERANEXUS PARTICIPATES IN SEVERAL LEADING SCIENTIFIC CONFERENCES AND BUSINESS CONVENTIONS
Lyon, France – 9 June 2022– 6 pm CEST – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the
DGAP-Adhoc: Newron präsentiert vielversprechende Zwischenergebnisse für Evenamide bei Patienten mit therapieresistenter Schizophrenie (TRS) auf dem 33. CINP Hybrid World Congress of Neuropsychopharmacology
DGAP-News: CytoTools AG: Zeichnung der Kapitalerhöhung der CytoTools AG abgeschlossen
DGAP-HV: Heidelberg Pharma AG: Bekanntmachung der Einberufung zur Hauptversammlung am 22.06.2022 in Ladenburg mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
DGAP-News: Drogeriemarktkette dm: Vermarktungsaktion für NanoRepro-Produkte in 2000 Filialen
DGAP-Adhoc: Heidelberg Pharma und Partner Huadong erhalten alle Genehmigungen für die angekündigte Transaktion von den Behörden und planen Kapitalmaßnahme
DGAP-News: Burcon kündigt Kreditrahmen in Höhe von 10 Millionen CAD durch Aktionär an
DGAP-News: CytoTools AG: HEUTE um 16:00 - Der Vorstand der CytoTools AG im Gespräch mit Aktionären/-innen
DGAP-News: Burcon informiert über aktuelle Entwicklungen
DGAP-News: Heidelberg Pharma AG: Zwischenmitteilung für die ersten drei Monate 2022
DGAP-News: CytoTools AG: CytoTools AG startet Kapitalmaßnahme und plant die Ausweitung seines Engagements mit innovativen biomedizinischen Projekten
Theranexus publishes its 2021 full-year results And announces a shift of its strategic focus to rare neurological diseases
Lyon, France – 25 April 2022 – 7:00 am CEST –Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating
THERANEXUS UNVEILS ITS SCIENTIFIC ADVANCES ON THE OCCASION OF WORLD RARE DISEASE DAY 2022
- · New milestone for NeuroLead, the active agent screening platform
- · New publications in scientific journals
- · Start of Phase I/II clinical trial for Batten disease
Lyon, 28 February 2022
THERANEXUS AND BBDF START RECRUITMENT FOR PHASE I/II TRIAL IN BATTEN DISEASE PATIENTS
Lyon, France – Austin, TX, USA - 3 February 2022 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates
THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2021 - IMPLEMENTATION OF A NEW EQUITY LINE
Lyon, 13 January 2022 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction
THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2022
Lyon, December 20, 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction
Lysogene Secures a €4.3 Million Non-dilutive Financing From Bpifrance to Support Its Development
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today that it has secured a €4.3
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
GenSight Biologics Reports Second Patient Case Showing Significant Visual Recovery after GS030 Optogenetic Treatment
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative
Valbiotis meldet auf der Jahrestagung der American Heart Association (AHA) positive präklinische Ergebnisse für TOTUM•070 gegen Hypercholesterinämie
Valbiotis (Paris: ALVAL) (FR0013254851 – ALVAL, PEA/KMU-qualifiziert), ein französisches Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und
Valbiotis Announces Positive Preclinical Results for TOTUM•070 in Hypercholesterolemia, Selected and Presented at the American Heart Association (AHA) Annual Meeting
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211114005021/en/
TOTUM•070 preclinical results AHA 2021 (Graphic
GenSight Biologics to Present New Clinical Data of LUMEVOQ® and GS030 Gene Therapies at the American Academy of Ophthalmology 2021 Meeting
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Sensorion to present in person at “Jefferies London Healthcare Conference”
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Sensorion Surpasses Enrollment Target for SENS-401 in SSNHL, Results Available in January 2022
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Sensorion to Present at “Jefferies Gene Therapy / Editing Summit”
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within